This policy brief outlines key considerations to facilitate effective transition to more clinically appropriate regimens as optimal antiretroviral medicines and dosage forms become available.
Transitioning to the 2021 WHO optimal formulary for antiretroviral drugs for children
Updated: Jan 28, 2022
Comments